Daridorexant is a medicinal product in clinical development for the treatment of adults with insomnia. Insomnia means regularly having problems sleeping, which results in impaired daytime functioning. Insomnia can be categorised according to its duration, into short-term insomnia (lasting less than 4 weeks) and long-term (or persistent) insomnia (lasting 4 weeks or longer).
Daridorexant is a drug which reduces excessive alertness, in contrast to treatments of insomnia that sedates the central nervous system. As a result, daridorexant offers the potential to induce and maintain sleep, through all stages of sleep. Daridorexant is quickly absorbed in the body, resulting in a fast onset of action. Daridorexant is given orally as tablets. If licensed, daridorexant could represent an additional treatment option for patients with insomnia.
Xeomin is one formulation of botulinum neurotoxin type A. It is injected into salivary glands and reduces saliva production. Currently, it is recommended as a specialist option for treating sialorrhea in children and adolescents, but is not yet licensed for this indication. It is an alternative to anticholinergic drugs which are also used to reduce saliva flow, but which can have side effects in a number of patients. If licensed, Xeomin will offer an additional treatment option for chronic sialorrhea in children and adolescents aged 2 to 17 years.